News Archives - Page 20 of 44 - Imaging Endpoints

Imaging Endpoints Performs Thousands of Real-Time Reads Monthly

April 8, 2021 - Imaging Endpoints leverages its global infrastructure, and offices in North America, Asia and Europe, to provide real-time read results to sponsors and their clinical sites in over 40 countries around the globe. Each month the Company… Read More

Clinical Endpoints Well-Positioned to Transition Treatments to Future Patients

April 6, 2021 - As researchers worldwide develop new therapies for diseases such as Alzheimer's, Donnell Carmichael, VP for Clinical Research Operations, says Clinical Endpoints is well-positioned to help transition these treatments to future patients. "Clinical Endpoints is introducing physicians… Read More

Registration Trials Help Improve Outlook for Prostate Cancer

April 2, 2021 - Through our work in supporting successful registration trials that are improving overall survival and radiographic progression-free survival in patients with prostate cancer, as well as our novel imaging techniques, we are joining and winning the fight… Read More

Imaging Endpoints Expands Research Services

Global Imaging Leader Formally Launches Research Endpoints March 31, 2021 - Scottsdale, Arizona – Imaging Endpoints (IE) announced today that it has formally established Research Endpoints, LLC, as a new wholly-owned subsidiary to manage the extraordinary demand for its exploratory… Read More

Novartis Announces Positive Result of Phase III Study With Radioligand Therapy ¹⁷⁷Lu-PSMA-617 in Patients With Advanced Prostate Cancer

Basel, March, 23, 2021 — Novartis has reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of ¹⁷⁷Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone.